KRYS

Krystal Biotech's stock price has been positively impacted by strong financial performance and analyst sentiment. The company reported strong Q1 2026 earnings with an EPS of $1.83 and revenue of $116.4 million, exceeding expectations, driven by a 32% year-over-year increase in net product revenue from VYJUVEK. The stock price reached an all-time high of $302 on May 5, 2026. The company also reported strong Q4 2025 earnings with an EPS of $1.70 and revenue of $107.11 million. Krystal Biotech's stock has shown a significant 1-year return of 76.81% and a year-to-date return of 11.93% as of April 22, 2026. Institutional ownership is high.